CDMO News

INCOG BioPharma: Pioneering CDMO Receives FDA Approval

  • INCOG BioPharma Services has received FDA approval to produce a commercially approved drug product, as it expands to add 100 million units of pre-filled syringe and cartridge capacity.
  • INCOG’s facility was recently recognised as a finalist in the Facility of the Year Awards by the ISPE.

INCOG BioPharma Services, a biopharmaceutical contract manufacturing organisation, announced that its sterile injectable manufacturing facility has received approval from the U.S. Food and Drug Administration (FDA) to produce a commercially approved drug product.

The FDA approval comes after a rigorous inspection of INCOG’s facility and quality systems. Notably, the inspection resulted in zero Form 483 observations, underscoring the company’s commitment to excellence in quality systems and aseptic manufacturing practices. “We are thrilled to receive our initial FDA approval,” said JR Humbert, VP of Quality for INCOG. “This remarkable achievement is a testament to the incredible team we have put together and our dedication to quality as a foundational element of our mission to be a best-in-class CDMO.”

The company is currently expanding to add 100 million units of pre-filled syringe and cartridge capacity in 2025. The company’s second barrier isolator filling line is scheduled for delivery in October 2024, with GMP readiness targeted for Q2 2025. This expansion brings the site’s total capacity to approximately 140 million units per year and provides a clear path for additional commercial drug production at the facility.

“Our vision has always been to support customers from clinical stages all the way through to commercialization,” said Alex Haig, VP of Operations at INCOG. “We value creating long-term relationships with our clients, with the goal of accelerating their innovative therapies to the patients that need them.”

In addition to the FDA approval, INCOG’s facility was recently recognised as a finalist in the Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE). This recognition reflects the company’s innovative approach to facility design and manufacturing processes, setting a benchmark for excellence in the industry. Furthermore, for the third year in a row, INCOG received the Best Places to Work award from the Indiana Chamber of Commerce, which recognizes companies committed to fostering a positive work environment and supporting employee growth and satisfaction. “We are proud of the recognition we have received for our commitment to excellence, both in our manufacturing facility and as an employer,” said Tedd Green, COO and co-founder at INCOG. “These accolades reinforce our dedication to delivering high-quality products and creating a positive workplace culture.”

ELEARNING
Learn the essentials of successful biopharma outsourcing

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

Sign up to our free weekly newsletter for all the latest contract manufacturing news.  Register here

ELEARNING

Learn the essentials of successful biopharma outsourcing

New eLearning course distils 100+ expert interviews into 10 engaging modules.

tick Overview of outsourcing trends 
tick Expert insights and case studies 
tick Helpful resources and quizzes

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.